Geode Capital Management LLC Buys 14,151 Shares of STERIS plc $STE

Geode Capital Management LLC raised its stake in shares of STERIS plc (NYSE:STE) by 0.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,523,620 shares of the medical equipment provider’s stock after acquiring an additional 14,151 shares during the period. Geode Capital Management LLC’s holdings in STERIS were worth $637,259,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of STERIS by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 12,286,535 shares of the medical equipment provider’s stock worth $3,114,882,000 after purchasing an additional 73,014 shares during the period. State Street Corp increased its holdings in STERIS by 4.0% in the 3rd quarter. State Street Corp now owns 4,354,839 shares of the medical equipment provider’s stock worth $1,077,564,000 after acquiring an additional 166,736 shares during the last quarter. Orbis Allan Gray Ltd increased its holdings in STERIS by 36.0% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock worth $504,486,000 after acquiring an additional 556,088 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in STERIS by 16.4% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,567,238 shares of the medical equipment provider’s stock valued at $387,797,000 after buying an additional 221,199 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in STERIS by 4.9% during the 3rd quarter. Invesco Ltd. now owns 1,280,142 shares of the medical equipment provider’s stock valued at $316,758,000 after buying an additional 59,443 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors.

STERIS Price Performance

Shares of STERIS stock opened at $212.52 on Friday. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25. The company has a market cap of $20.84 billion, a PE ratio of 26.80 and a beta of 0.95. The business has a 50 day moving average of $218.24 and a 200 day moving average of $240.93. STERIS plc has a 52 week low of $195.14 and a 52 week high of $269.44.

STERIS (NYSE:STE) last announced its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.59 billion. STERIS had a net margin of 13.18% and a return on equity of 14.15%. STERIS’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.74 EPS. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, equities research analysts forecast that STERIS plc will post 11.18 earnings per share for the current year.

STERIS Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be issued a $0.63 dividend. The ex-dividend date is Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. STERIS’s dividend payout ratio is 31.78%.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Piper Sandler restated an “overweight” rating and issued a $270.00 target price on shares of STERIS in a research note on Thursday, May 21st. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 16th. KeyCorp cut their target price on STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Finally, Weiss Ratings lowered STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $278.00.

Insider Transactions at STERIS

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total value of $734,876.58. Following the completion of the transaction, the director owned 705 shares in the company, valued at approximately $167,233.05. This represents a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.07% of the company’s stock.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.